Skip to main content

BioSniper ranking

Nearest Upcoming Biotech Catalysts

Biotech catalysts — PDUFA decisions, AdCom meetings, clinical trial readouts, FDA approvals, and patent expirations — are the events that move small- and mid-cap biotech stocks. This ranking merges every catalyst type into a single list, nearest first, so you can see what is coming across the sector.

Ranked entities
100
Freshness
No verified data date available
Method
Published source data
BioSniper AIPage evidence connected

Prepared research question

Why is Phase 1 Start: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics an — Ne → GHRS in this position, and what could change the ranking?

Run cited research

Traceable citations · Unknowns marked

  1. 1Phase 1 Start: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics anGH Research PLC (GHRS)Aug 30, 2026Phase1 Start
  2. 2Phase 3 Topline: Comparison of Efficacy of Tranexamic Acid Versus Vasopressin in Blood Loss Among Placenta Previa PatENANTA PHARMACEUTICALS INC (ENTA)Aug 31, 2026Phase3 Topline
  3. 3Phase 2 Start: A Phase 2A, Proof-of-Concept, Randomized, Parallel, Double-Blind, Placebo-Controlled Study to AssessPTC THERAPEUTICS, INC. (PTCT)Aug 31, 2026Phase2 Start
  4. 4Phase 2 Start: A Phase 1/2 Open-Label, Safety and Efficacy Study of Neoadjuvant Fianlimab (Anti-LAG-3 Antibody) in REGENERON PHARMACEUTICALS, INC. (REGN)Aug 31, 2026Phase2 Start
  5. 5Phase 2 Start: A Phase 2 Study of Tislelizumab Administered With Alternative Dosing Schedules Plus Chemotherapy as BeOne Medicines Ltd. (ONC)Aug 31, 2026Phase2 Start
  6. 6Phase 2 Start: A Phase 2, Multicenter, Open-Label Study of Zolacabtagene Autoleucel (BMS-986353), CD19-Targeted NEXBRISTOL MYERS SQUIBB CO (BMY)Aug 31, 2026Phase2 Start
  7. 7Phase 3 Topline: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial ChemoeASTRAZENECA PLC (AZN)Aug 31, 2026Phase3 Topline
  8. 8Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With An Open Label SafetyZenas BioPharma, Inc. (ZBIO)Aug 31, 2026Phase3 Topline
  9. 9Phase 2 Start: A Phase 1b/2a Open-Label, Dose-Exploration Study to Investigate the Safety and Tolerability of SubreOpus Genetics, Inc. (IRD)Sep 1, 2026Phase2 Start
  10. 10Phase 3 Topline: A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain Alkermes plc. (ALKS)Sep 1, 2026Phase3 Topline
  11. 11Phase 3 Topline: Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of SPN-812 for the TreatmenSUPERNUS PHARMACEUTICALS, INC. (SUPN)Sep 1, 2026Phase3 Topline
  12. 12Phase 2 Start: A Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase 2 Trial to Evaluate the Safety anTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)Sep 1, 2026Phase2 Start
  13. 13Phase 2 Start: A Phase 2, Multicenter, Double-Blind, Randomized, Controlled Trial of the Safety and Immunogenicity Arcturus Therapeutics Holdings Inc. (ARCT)Sep 1, 2026Phase2 Start
  14. 14Phase 2 Start: A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in ParIOVANCE BIOTHERAPEUTICS, INC. (IOVA)Sep 1, 2026Phase2 Start
  15. 15Phase 1 Start: Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and ZabaImmunityBio, Inc. (IBRX)Sep 1, 2026Phase1 Start
  16. 16Phase 2 Readout: rademikibartConnect Biopharma Holdings Ltd (CNTB)Sep 1, 2026Phase2 Topline
  17. 17Phase 3 Topline: Opiate-sparing Post-operative Pain Control in Septorhinoplasty: A Prospective Randomized, Double BliUNITED THERAPEUTICS Corp (UTHR)Sep 1, 2026Phase3 Topline
  18. 18Phase 3 Topline: A Multicenter, Double-blind, Randomized Study to Evaluate the Effects of Tasimelteon vs. Placebo in Vanda Pharmaceuticals Inc. (VNDA)Sep 1, 2026Phase3 Topline
  19. 19Phase 1 Start: A Phase 1a/1b, First Time in Human Study of CT-202, A Nectin-4 Directed Bispecific Antibody, in PartContext Therapeutics Inc. (CNTX)Sep 1, 2026Phase1 Start
  20. 20Phase 2 Start: A Phase 2a Study for the Evaluation of Safety and Efficacy of Humacyte's Coronary Tissue Engineered Humacyte Inc. (HUMA)Sep 1, 2026Phase2 Start
  21. 21Phase 3 Topline: A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess CoCYBIN INC. (HELP)Sep 1, 2026Phase3 Topline
  22. 22Phase 3 Topline: Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran inARROWHEAD PHARMACEUTICALS, INC. (ARWR)Sep 1, 2026Phase3 Topline
  23. 23Phase 3 Topline: Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in ARROWHEAD PHARMACEUTICALS, INC. (ARWR)Sep 1, 2026Phase3 Topline
  24. 24Phase 2 Start: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial to AsseSpyre Therapeutics, Inc. (SYRE)Sep 1, 2026Phase2 Start
  25. 25Phase 3 Topline: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and EffiARDELYX, INC. (ARDX)Sep 1, 2026Phase3 Topline
  26. 26Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the EffVeradermics Incorporated (MANE)Sep 1, 2026Phase3 Topline
  27. 27Phase 1 Start: Efficacy and Safety of Yiqi Wenyang Sanhan Formula Combined With Acupoint Application in Patients WiINTEGRATED BIOPHARMA INC (INBP)Sep 1, 2026Phase1 Start
  28. 28Phase 2 Start: A Phase 2, Open-Label Study of CTX-471 in Patients With NCAM Positive TumorsCompass Therapeutics, Inc. (CMPX)Sep 1, 2026Phase2 Start
  29. 29Phase 3 Topline: A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel ForUroGen Pharma Ltd. (URGN)Sep 1, 2026Phase3 Topline
  30. 30Phase 2 Start: Ultra-low Dose Transdermal Estradiol Therapy in Prepubertal Girls With Turner Syndrome and Primary OGH Research PLC (GHRS)Sep 1, 2026Phase2 Start
  31. 31Phase 2 Start: Investigating Novel Interventions for Low Back Pain in US Military Veterans: A Randomized ControlledGH Research PLC (GHRS)Sep 1, 2026Phase2 Start
  32. 32Phase 1 Start: An Open-Label, Four-Treatment, Parallel Study of the Comparative Pharmacokinetics of a Progesterone Dare Bioscience, Inc. (DARE)Sep 1, 2026Phase1 Start
  33. 33Phase 2 Start: An Open-Label Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced Hepatocellular CarIO Biotech, Inc. (IOBTQ)Sep 1, 2026Phase2 Start
  34. 34Phase 2 Start: 2-Hydroxybenzylamine (2-HOBA) Phase 1b/2a Proof-of Concept, Dose-Finding, Biomarker Study in Early AIO Biotech, Inc. (IOBTQ)Sep 1, 2026Phase2 Start
  35. 35Phase 2 Readout: ost-her2OS Therapies Inc (OSTX)Sep 1, 2026Phase2 Topline
  36. 36Phase 2 Start: Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Efficacy and Safety of VXBiotech Inc. (XBIT)Sep 1, 2026Phase2 Start
  37. 37Phase 2 Start: A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose StudyKorro Bio, Inc. (KRRO)Sep 1, 2026Phase2 Start
  38. 38Phase 1 Start: A Placebo-Controlled, Single- and Multiple-Ascending Dose, Phase 1 Study to Evaluate the Safety, TolELI LILLY & Co (LLY)Sep 1, 2026Phase1 Start
  39. 39Phase 1 Start: A Master Protocol for Phase 1 Clinical Trials of Multiple Amyloid-Targeting Therapies for the TreatmELI LILLY & Co (LLY)Sep 1, 2026Phase1 Start
  40. 40Phase 2 Start: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and SafetELI LILLY & Co (LLY)Sep 1, 2026Phase2 Start
  41. 41Phase 3 Topline: A Phase 3, Multicenter, Open-label, Single-arm Study to Assess the Efficacy and Safety of ApremilastAMGEN INC (AMGN)Sep 3, 2026Phase3 Topline
  42. 42Phase 1 Start: A Phase 1, Randomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Safety andZai Lab Ltd (ZLAB)Sep 3, 2026Phase1 Start
  43. 43Phase 1 Start: A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and BeOne Medicines Ltd. (ONC)Sep 4, 2026Phase1 Start
  44. 44Phase 1 Start: A Master Protocol for a Phase 1b Double-Blind, Randomized Study to Assess the Safety, Tolerability, REGENERON PHARMACEUTICALS, INC. (REGN)Sep 9, 2026Phase1 Start
  45. 45Phase 3 Topline: PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a ChaNovartis AG (NVS)Sep 10, 2026Phase3 Topline
  46. 46Phase 2 Start: A Phase IIb Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-range Study to Assess thNovartis AG (NVS)Sep 10, 2026Phase2 Start
  47. 47Phase 2 Start: A Multicenter, Phase 2, Open-Label Study Evaluating the Safety and Efficacy of KER-065 in ParticipanKeros Therapeutics, Inc. (KROS)Sep 14, 2026Phase2 Start
  48. 48Phase 2 Start: A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, PharmacokineticBRISTOL MYERS SQUIBB CO (BMY)Sep 15, 2026Phase2 Start
  49. 49Phase 2 Start: Phase 1b/2, Open-Label Clinical Trial Evaluating the Safety and Efficacy of Nogapendekin Alfa InbakiImmunityBio, Inc. (IBRX)Sep 15, 2026Phase2 Start
  50. 50Phase 1 Start: A Phase 1 Study to Evaluate the Mass Balance, Metabolism, Excretion, and Pharmacokinetics of [14C]NaBRISTOL MYERS SQUIBB CO (BMY)Sep 16, 2026Phase1 Start
  51. 51Phase 1 Start: An Open-Label, Multi-Center Phase I Study to Investigate the Safety and Tolerability of REGN17235 inREGENERON PHARMACEUTICALS, INC. (REGN)Sep 17, 2026Phase1 Start
  52. 52Phase 3 Topline: A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With ChemotheraASTRAZENECA PLC (AZN)Sep 17, 2026Phase3 Topline
  53. 53Phase 3 Topline: A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of FluticasoneTeva Pharmaceutical Industries Limited (TEVA)Sep 19, 2026Phase3 Topline
  54. 54Phase 3 Topline: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide MonotPFIZER INC (PFE)Sep 19, 2026Phase3 Topline
  55. 55PDUFA Date: zilganersenIONIS PHARMACEUTICALS INC (IONS)Sep 22, 2026PDUFA
  56. 56Phase 2 Start: A Phase 2, Open-Label, Master Protocol Study to Evaluate Safety and Efficacy of Treatment CombinatioAbbVie Inc. (ABBV)Sep 22, 2026Phase2 Start
  57. 57Phase 1 Start: A Multi-center, Open-label, Phase I Study Evaluating Safety, Tolerability, Pharmacokinetics and AntiAdlai Nortye Ltd. (ANL)Sep 23, 2026Phase1 Start
  58. 58Phase 2 Start: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial to EvaluatGH Research PLC (GHRS)Sep 23, 2026Phase2 Start
  59. 59Phase 3 Topline: A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 VNovartis AG (NVS)Sep 23, 2026Phase3 Topline
  60. 60Phase 3 Topline: A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in CombinatiASTRAZENECA PLC (AZN)Sep 24, 2026Phase3 Topline
  61. 61Phase 3 Topline: A PHASE 1 STUDY TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE AND PHASE 2/3 PIOcugen, Inc. (OCGN)Sep 28, 2026Phase3 Topline
  62. 62Phase 3 Topline: An Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous SonelokiMoonLake Immunotherapeutics (MLTX)Sep 28, 2026Phase3 Topline
  63. 63Phase 2 Readout: halneuronDogwood Therapeutics, Inc. (DWTX)Sep 30, 2026Phase2 Topline
  64. 64Phase 2 Readout: revitaFractyl Health Inc. (GUTS)Sep 30, 2026Phase2 Topline
  65. 65Phase 2 Readout: nimacimabSkye Bioscience, Inc. (SKYE)Sep 30, 2026Phase2 Topline
  66. 66Phase 1 Start: A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and PharmacokiUroGen Pharma Ltd. (URGN)Sep 30, 2026Phase1 Start
  67. 67Phase 2 Readout: bezisterimBIOVIE INC. (BIVI)Sep 30, 2026Phase2 Topline
  68. 68Phase 2 Readout: divesiranSilence Therapeutics Plc (SLN)Sep 30, 2026Phase2 Topline
  69. 69Phase 2 Start: A Phase 2 Open-Label Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of TelisotuAbbVie Inc. (ABBV)Sep 30, 2026Phase2 Start
  70. 70Phase 2 Readout: esk-001ALUMIS INC. (ALMS)Sep 30, 2026Phase2 Topline
  71. 71Phase 2 Readout: envudeucitinibALUMIS INC. (ALMS)Sep 30, 2026Phase2 Topline
  72. 72Phase 2 Readout: RASpyre Therapeutics, Inc. (SYRE)Sep 30, 2026Phase2 Topline
  73. 73Phase 2 Readout: piclidenosonCan-Fite BioPharma Ltd. (CANF)Sep 30, 2026Phase2 Topline
  74. 74Phase 2 Readout: namodenosonCan-Fite BioPharma Ltd. (CANF)Sep 30, 2026Phase2 Topline
  75. 75Phase 2 Readout: nexicart-2JOHNSON & JOHNSON (JNJ)Sep 30, 2026Phase2 Topline
  76. 76Phase 1 Start: A Phase 1 Dose-Escalation Study of XL092 in Children and Adolescents With Relapsed or Refractory SolEXELIXIS, INC. (EXEL)Sep 30, 2026Phase1 Start
  77. 77Phase 3 Topline: A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line ASTRAZENECA PLC (AZN)Sep 30, 2026Phase3 Topline
  78. 78Phase 2 Readout: abcl635AbCellera Biologics Inc. (ABCL)Sep 30, 2026Phase2 Topline
  79. 79Phase 3 Topline: An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and AcARGENX SE (ARGX)Sep 30, 2026Phase3 Topline
  80. 80Phase 2 Readout: pali-2108PALISADE BIO, INC. (PALI)Sep 30, 2026Phase2 Topline
  81. 81Phase 2 Readout: sl-325Shattuck Labs, Inc. (STTK)Sep 30, 2026Phase2 Topline
  82. 82Phase 2 Start: A Phase 2 Study of Alisertib in Combination With Paclitaxel in Patients With Small Cell Lung CancerPUMA BIOTECHNOLOGY, INC. (PBYI)Sep 30, 2026Phase2 Start
  83. 83Phase 2 Readout: ep-104giEUPRAXIA PHARMACEUTICALS INC. (EPRX)Sep 30, 2026Phase2 Topline
  84. 84Phase 2 Readout: nxc-201Immix Biopharma, Inc. (IMMX)Sep 30, 2026Phase2 Topline
  85. 85Phase 2 Readout: intranasal foralumabTiziana Life Sciences Ltd (TLSA)Sep 30, 2026Phase2 Topline
  86. 86Phase 2 Readout: pipeline candidateMapLight Therapeutics, Inc. (MPLT)Sep 30, 2026Phase2 Topline
  87. 87Phase 2 Readout: ml-007c-maMapLight Therapeutics, Inc. (MPLT)Sep 30, 2026Phase2 Topline
  88. 88Phase 2 Readout: gt-02287Gain Therapeutics, Inc. (GANX)Sep 30, 2026Phase2 Topline
  89. 89Phase 2 Readout: evorpaceptALX ONCOLOGY HOLDINGS INC (ALXO)Sep 30, 2026Phase2 Topline
  90. 90Phase 2 Start: Phase 2B Randomized, Placebo-Controlled, Double-Blind, Repeat Dose Parallel Study in Participants WiVogenx, Inc. (VOGX)Oct 1, 2026Phase2 Start
  91. 91Phase 2 Start: A Phase 1/2, First-in-human, Double-blind, Placebo-controlled Study to Assess Dose, Safety, and EffiUltragenyx Pharmaceutical Inc. (RARE)Oct 1, 2026Phase2 Start
  92. 92Phase 3 Topline: A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of AficaCYTOKINETICS INC (CYTK)Oct 1, 2026Phase3 Topline
  93. 93Phase 3 Topline: Diagnostic Testing of Post-Traumatic Stress Disorder (PTSD) Using the Senseye Diagnostic Tool in AduCrinetics Pharmaceuticals, Inc. (CRNX)Oct 1, 2026Phase3 Topline
  94. 94Phase 1 Start: A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics oELI LILLY & Co (LLY)Oct 1, 2026Phase1 Start
  95. 95Phase 3 Topline: Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and PharmELI LILLY & Co (LLY)Oct 1, 2026Phase3 Topline
  96. 96Phase 3 Topline: A Phase 2/3 Multicenter, Randomization, Double-Blind, Placebo-Controlled, Study to Evaluate the EffiBiohaven Ltd. (BHVN)Oct 1, 2026Phase3 Topline
  97. 97Phase 3 Topline: A Phase 3 Study of Tapinarof for the Treatment of Plaque Psoriasis in Pediatric SubjectsOrganon & Co. (OGN)Oct 1, 2026Phase3 Topline
  98. 98Phase 2 Start: A Phase 1/2, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Atrium Therapeutics Inc. (RNA)Oct 1, 2026Phase2 Start
  99. 99Phase 2 Start: A Phase Ib/Phase II Trial With Capivasertib Plus Immunotherapy in Bladder CancerGH Research PLC (GHRS)Oct 1, 2026Phase2 Start
  100. 100Phase 2 Start: The Effects of SGLT2 Inhibition on Vascular Health and Physical Function in Veterans With CKDGH Research PLC (GHRS)Oct 1, 2026Phase2 Start

Ranked by soonest date. Only dates confirmed in a primary source (SEC filing, FDA source, or company disclosure) are shown; speculative far-future dates are excluded.

Frequently asked questions

What counts as a biotech catalyst?

A catalyst is a scheduled or expected event that can materially move a stock — most commonly PDUFA dates, AdCom meetings, Phase 2/3 trial readouts, FDA approvals, and patent expirations.

How are catalyst dates verified?

BioSniper only shows a date when it appears in a primary source (SEC filing, FDA source, or company disclosure); speculative far-future dates are excluded.

How current is this ranking?

Event dates and source records are shown with their available source context.

From ranked signal to decision rule

Decide how this ranking should affect your thesis

Turn the ranking field into a criterion, add your own thresholds, and require supporting company evidence before it influences a decision.

Turn this signal into a thesis rule — freeTurn this signal into a thesis rule